Use of Mucoactive Agents in Cystic Fibrosis: A Consensus Survey of Italian Specialists

Overview

Journal Health Sci Rep

Specialty General Medicine

Date 2022 Jun 9

PMID 35677472

Authors

Sonia Volpi

Vincenzo Carnovale

Carla Colombo

Valeria Raia

Francesco Blasi

Giovanni Pappagallo

Affiliations

Soon will be listed here.

Abstract

Background: The goal of mucoactive therapies in cystic fibrosis (CF) is to enhance sputum clearance and to reduce a progressive decline in lung function over the patient's lifetime. We aimed to investigate the level of consensus among specialists from Italian CF Centers on appropriateness of therapeutic use of dornase alfa (rhDNase) for CF patients.

Method: A consensus on appropriate prescribing in CF mucoactive agents was appraised by an online Delphi method, based on a panel of 27 pulmonologists, coordinated by a Scientific Committee of six experts in medical care of patients with CF.

Results: Full or very high consensus was reached on several issues related to therapeutic use of dornase alfa for CF patients in clinical practice.

Conclusions: The consensus reached on a number of topics regarding use of mucoactive agents in patients with CF can help guide clinicians in daily practice based on expert experience and define the most appropriate therapeutic strategy for the individual patient.

Citing Articles

Use of mucoactive agents in cystic fibrosis: A consensus survey of Italian specialists.

Volpi S, Carnovale V, Colombo C, Raia V, Blasi F, Pappagallo G Health Sci Rep. 2022; 5(4):e604.

PMID: 35677472 PMC: 9169509. DOI: 10.1002/hsr2.604.

References

Wahl A, Rustoen T, Hanestad B, Gjengedal E, Moum T . Living with cystic fibrosis: impact on global quality of life. Heart Lung. 2005; 34(5):324-31. DOI: 10.1016/j.hrtlng.2004.11.002. View

Sagel S, Kapsner R, Osberg I, Sontag M, Accurso F . Airway inflammation in children with cystic fibrosis and healthy children assessed by sputum induction. Am J Respir Crit Care Med. 2001; 164(8 Pt 1):1425-31. DOI: 10.1164/ajrccm.164.8.2104075. View

Ratjen F, Davis S, Stanojevic S, Kronmal R, Stukovsky K, Jorgensen N . Inhaled hypertonic saline in preschool children with cystic fibrosis (SHIP): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet Respir Med. 2019; 7(9):802-809. DOI: 10.1016/S2213-2600(19)30187-0. View

Ratjen F, Paul K, van Koningsbruggen S, Breitenstein S, Rietschel E, Nikolaizik W . DNA concentrations in BAL fluid of cystic fibrosis patients with early lung disease: influence of treatment with dornase alpha. Pediatr Pulmonol. 2004; 39(1):1-4. DOI: 10.1002/ppul.20134. View

Castellani C, Duff A, Bell S, Heijerman H, Munck A, Ratjen F . ECFS best practice guidelines: the 2018 revision. J Cyst Fibros. 2018; 17(2):153-178. DOI: 10.1016/j.jcf.2018.02.006. View

Shak S . Aerosolized recombinant human DNase I for the treatment of cystic fibrosis. Chest. 1995; 107(2 Suppl):65S-70S. DOI: 10.1378/chest.107.2_supplement.65s. View

Lomas P . Enhancing adherence to inhaled therapies in cystic fibrosis. Ther Adv Respir Dis. 2014; 8(2):39-47. DOI: 10.1177/1753465814524471. View

Heijerman H, Westerman E, Conway S, Touw D, Doring G . Inhaled medication and inhalation devices for lung disease in patients with cystic fibrosis: A European consensus. J Cyst Fibros. 2009; 8(5):295-315. DOI: 10.1016/j.jcf.2009.04.005. View

Brody A, Sucharew H, Campbell J, Millard S, Molina P, Klein J . Computed tomography correlates with pulmonary exacerbations in children with cystic fibrosis. Am J Respir Crit Care Med. 2005; 172(9):1128-32. DOI: 10.1164/rccm.200407-989OC. View

10.

Volpi S, Carnovale V, Colombo C, Raia V, Blasi F, Pappagallo G . Use of mucoactive agents in cystic fibrosis: A consensus survey of Italian specialists. Health Sci Rep. 2022; 5(4):e604. PMC: 9169509. DOI: 10.1002/hsr2.604. View

11.

Riordan J, Rommens J, Kerem B, Alon N, Rozmahel R, Grzelczak Z . Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. Science. 1989; 245(4922):1066-73. DOI: 10.1126/science.2475911. View

12.

Dentice R, Elkins M . Timing of dornase alfa inhalation for cystic fibrosis. Cochrane Database Syst Rev. 2018; 11:CD007923. PMC: 6433332. DOI: 10.1002/14651858.CD007923.pub5. View

13.

Macdonald M, Martin-Misener R, Helwig M, Smith L, Godfrey C, Curran J . Experiences of adults with cystic fibrosis in adhering to medication regimens: a qualitative systematic review. JBI Database System Rev Implement Rep. 2016; 14(5):258-85. DOI: 10.11124/JBISRIR-2016-002362. View

14.

Konstan M, VanDevanter D, Rasouliyan L, Pasta D, Yegin A, Morgan W . Trends in the use of routine therapies in cystic fibrosis: 1995-2005. Pediatr Pulmonol. 2010; 45(12):1167-72. PMC: 4112572. DOI: 10.1002/ppul.21315. View

15.

Konstan M, Ratjen F . Effect of dornase alfa on inflammation and lung function: potential role in the early treatment of cystic fibrosis. J Cyst Fibros. 2011; 11(2):78-83. PMC: 4090757. DOI: 10.1016/j.jcf.2011.10.003. View

16.

Rubin B, Ramirez O, King M . Mucus-depleted frog palate as a model for the study of mucociliary clearance. J Appl Physiol (1985). 1990; 69(2):424-9. DOI: 10.1152/jappl.1990.69.2.424. View

17.

Eakin M, Bilderback A, Boyle M, Mogayzel P, Riekert K . Longitudinal association between medication adherence and lung health in people with cystic fibrosis. J Cyst Fibros. 2011; 10(4):258-64. PMC: 3114200. DOI: 10.1016/j.jcf.2011.03.005. View

18.

Yang C, Montgomery M . Dornase alfa for cystic fibrosis. Cochrane Database Syst Rev. 2018; 9:CD001127. PMC: 6513278. DOI: 10.1002/14651858.CD001127.pub4. View

19.

Fuchs H, Borowitz D, Christiansen D, Morris E, Nash M, Ramsey B . Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. The Pulmozyme Study Group. N Engl J Med. 1994; 331(10):637-42. DOI: 10.1056/NEJM199409083311003. View

20.

Sawicki G, Heller K, Demars N, Robinson W . Motivating adherence among adolescents with cystic fibrosis: youth and parent perspectives. Pediatr Pulmonol. 2014; 50(2):127-36. PMC: 4160425. DOI: 10.1002/ppul.23017. View